These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 31519767)
1. Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells. Liu X; Miao W; Huang M; Li L; Dai X; Wang Y Mol Cell Proteomics; 2019 Nov; 18(11):2273-2284. PubMed ID: 31519767 [TBL] [Abstract][Full Text] [Related]
2. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells. Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266 [TBL] [Abstract][Full Text] [Related]
4. Adenylate Kinase 4 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an m Liu X; Gonzalez G; Dai X; Miao W; Yuan J; Huang M; Bade D; Li L; Sun Y; Wang Y Mol Ther; 2020 Dec; 28(12):2593-2604. PubMed ID: 32956623 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells. Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787 [TBL] [Abstract][Full Text] [Related]
6. ATF3 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an Liu X; Yuan J; Zhang X; Li L; Dai X; Chen Q; Wang Y Chem Res Toxicol; 2021 Jul; 34(7):1814-1821. PubMed ID: 34213887 [TBL] [Abstract][Full Text] [Related]
7. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling. Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736 [TBL] [Abstract][Full Text] [Related]
8. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells. Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898 [TBL] [Abstract][Full Text] [Related]
9. MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells. Kim S; Jeon M; Lee JE; Nam SJ Oncol Rep; 2016 Apr; 35(4):2398-404. PubMed ID: 26780941 [TBL] [Abstract][Full Text] [Related]
10. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells. Nguyen Hoang AT; Hoe KL; Lee SJ PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751 [TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Zhou C; Zhong Q; Rhodes LV; Townley I; Bratton MR; Zhang Q; Martin EC; Elliott S; Collins-Burow BM; Burow ME; Wang G Breast Cancer Res; 2012 Mar; 14(2):R45. PubMed ID: 22417809 [TBL] [Abstract][Full Text] [Related]
12. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells. Kim HS; Tian L; Jung M; Choi SK; Sun Y; Kim H; Moon WK PLoS One; 2015; 10(10):e0141110. PubMed ID: 26496360 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641 [TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324 [TBL] [Abstract][Full Text] [Related]
16. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895 [TBL] [Abstract][Full Text] [Related]
17. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709 [TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. Wu C; Luo J Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells. Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway. Lu PW; Li L; Wang F; Gu YT J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]